A software system which helps women manage gestational diabetes is to be rolled out across another three NHS trusts.
Developed by British artificial intelligence company Sensyne Health, GDm-Health comprises a patient app and software for clinicians.
The smartphone app is connected to a wireless blood glucose monitor. Together, they can be used to submit blood glucose measurements, text-based observations and call-back requests from an expectant mum to a clinician at her chosen hospital.
The clinical software then uses an algorithm to identify the patients most in need of clinician input, with staff able to communicate directly with patients through the system.
GDm-Health has undergone a two-year clinical evaluation in the NHS, which involved more than 1,000 women.
The technology is already available to pregnant women and their midwives at Oxford University Hospitals NHS Foundation Trust and Royal Berkshire NHS Foundation Trust.
Lucy Mackillop, consultant obstetric physician at Oxford University Hospitals NHS Foundation Trust and the clinical lead for the development of GDm-Health, said: “I am delighted that GDm-Health has made the transition to a commercial product and is available for implementation across the NHS.
“This is as a result of an enormous amount of work by the clinical and academic teams at Oxford University Hospitals NHS Foundation Trust and University of Oxford and by Sensyne Health to have taken our prototype and transformed it into a sustainable scalable product.”
Three additional NHS trusts will be implementing GDm-Health in the near feature, including Buckinghamshire Healthcare NHS Trust, Croydon Health Services NHS Trust and Milton Keynes University Hospital NHS Foundation Trust.
Paul Drayson, CEO of Sensyne Health, said he was looking forward to the “wider adoption” of GDm-Health “in the coming months”.
Sensyne Health recently announced plans to float on the stock exchange in a bid to raise £60 million.
The Oxford-based company has also applied AI algorithms, developed by researchers at the University of Oxford and Oxford University Hospitals NHS Foundation Trust, to anonymised patient data with a view to finding clinical solutions which can later to sold to pharmaceutical companies.
